Treatment of rheumatic musculoskeletal disorders

被引:0
|
作者
W. Watson Buchanan
K. D. Rainsford
Colin A. Kean
Walter F. Kean
机构
[1] McMaster University,Department of Medicine
[2] Sheffield Hallam University,undefined
[3] Haldimand War Memorial Hospital,undefined
来源
Inflammopharmacology | 2024年 / 32卷
关键词
Medications; Therapeutics; Musculoskeletal pain;
D O I
暂无
中图分类号
学科分类号
摘要
Non-medicinal therapies with water, salts, exercise, massage, supportive devices, and electricity have been used for centuries and continue to be of benefit for some people with musculoskeletal disorders. Historical texts refer to the two electuaries mithridatium and theriaca as early therapeutic attempts of man to provide relief of musculoskeletal symptoms and attempt disease cures. For over 200 years, morphine-derived products have been used for musculoskeletal pain. The development of acetyl salicylic acid was a major breakthrough in joint pain management. This was followed by the introduction of nonsteroidal anti-inflammatory agents, paracetamol, and the use of corticosteroids. The gold-based compounds were the initial disease-modifying drugs and have been followed by the highly successful biologics agents. The basic objectives of musculoskeletal pain management include: reduction or elimination of joint pain; improvement or restoration of joint function and mobility; improvement of muscle strength to protect cartilage, ligaments, and joint capsule; prevention and reduction of damage to joint cartilage and supporting structures.
引用
收藏
页码:29 / 36
页数:7
相关论文
共 50 条
  • [31] Rheumatic and musculoskeletal disorders induced by immune checkpoint inhibitors: Consequences on overall survival
    Adda, Leslie
    Batteux, Benjamin
    Saidak, Zuzana
    Poulet, Claire
    Arnault, Jean-Philippe
    Chauffert, Bruno
    Sejourne, Alice
    JOINT BONE SPINE, 2021, 88 (04)
  • [32] THE BIOLOGIC AGENT SB4 ETANERCEPT BIOSIMILAR IN THE TREATMENT OF AUTOIMMUNE RHEUMATIC DISORDERS: REMISSION OF MUSCULOSKELETAL AND OTHER MANIFESTATIONS
    Athanassiou, P.
    Devetzi, E.
    Athanassiou, L.
    Tsakiridis, P.
    Tzanavari, A.
    Gatsiou, M.
    Katsavouni, C.
    Kostoglou-Athanassiou, I.
    OSTEOPOROSIS INTERNATIONAL, 2019, 30 : S725 - S726
  • [33] Cell Therapies New Opportunities in the Treatment of rheumatic and musculoskeletal Diseases
    Alexander, T.
    Burmester, G.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2020, 79 (05): : 417 - 418
  • [34] Prevalence of musculoskeletal disorders and rheumatic diseases in the indigenous Qom population of Rosario, Argentina
    Quintana, Rosana
    Silvestre, Adriana M. R.
    Goni, Mario
    Garcia, Vanina
    Mathern, Nora
    Jorfen, Marisa
    Miljevic, Julio
    Dhair, Daniel
    Laithe, Matias
    Conti, Silvana
    Midauar, Fadua
    Celeste Martin, Maria
    Cecilia Barrios, Maria
    Nieto, Romina
    Prigione, Cristina
    Sanabria, Alvaro
    Gervasoni, Viviana
    Grabbe, Emilio
    Gontero, Romina
    Pelaez-Ballestas, Ingris
    Pons-Estel, Bernardo A.
    CLINICAL RHEUMATOLOGY, 2016, 35 : S5 - S14
  • [35] COMMON RHEUMATIC DISORDERS .1. RHEUMATIC FEVER - DIAGNOSIS AND TREATMENT
    MCEWEN, C
    AMERICAN PRACTITIONER AND DIGEST OF TREATMENT, 1961, 12 (04): : 251 - &
  • [36] RATIONAL USE OF ANALGESICS IN THE TREATMENT OF THE RHEUMATIC DISORDERS
    HART, FD
    DRUGS, 1987, 33 (01) : 85 - 93
  • [37] Future direction of pathogenesis and treatment for rheumatic disorders
    Steffen Gay
    Arthritis Research & Therapy, 14 (Suppl 1):
  • [38] SYMPOSIUM ON INDOMETHACIN . INDOMETHACIN IN TREATMENT OF RHEUMATIC DISORDERS
    THOMPSON, M
    PERCY, JS
    ANNALS OF THE RHEUMATIC DISEASES, 1965, 24 (02) : 177 - &
  • [39] Future direction of pathogenesis and treatment for rheumatic disorders
    Gay, Steffen
    ARTHRITIS RESEARCH & THERAPY, 2012, 14
  • [40] LOCAL CORTICOSTEROID INJECTION TREATMENT IN RHEUMATIC DISORDERS
    GRAY, RG
    TENENBAUM, J
    GOTTLIEB, NL
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 1981, 10 (04) : 231 - 254